BioArctic AB (publ) (LON:0RV2)

London flag London · Delayed Price · Currency is GBP · Price in SEK
312.32
-2.98 (-0.95%)
At close: Dec 30, 2025
53.75%
Market Cap2.22B
Revenue (ttm)151.29M
Net Income (ttm)78.93M
Shares Outn/a
EPS (ttm)0.89
PE Ratio28.19
Forward PE67.00
Dividendn/a
Ex-Dividend Daten/a
Volume5,071
Average Volume6,101
Open315.50
Previous Close315.30
Day's Range310.60 - 313.60
52-Week Range154.60 - 341.00
Beta-0.92
RSI52.50
Earnings DateFeb 18, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 107
Stock Exchange London Stock Exchange
Ticker Symbol 0RV2
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.